Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study.

about

Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study.

Item

http://www.wikidata.org/entity/Q47118771

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Predictors of adherence to a n ...... licy: A cross-sectional study.

@en

Predictors of adherence to a n ...... licy: A cross-sectional study.

@nl

type

Item

label

Predictors of adherence to a n ...... licy: A cross-sectional study.

@en

Predictors of adherence to a n ...... licy: A cross-sectional study.

@nl

prefLabel

Predictors of adherence to a n ...... licy: A cross-sectional study.

@en

Predictors of adherence to a n ...... licy: A cross-sectional study.

@nl

P1476

Predictors of adherence to a n ...... olicy: A cross-sectional study

@en

P2093

Christopher K Finch

http://www.w3.org/2001/XMLSchema#string

Ibrahim Sales

http://www.w3.org/2001/XMLSchema#string

Joanna Q Hudson

http://www.w3.org/2001/XMLSchema#string

Mary E D Yates

http://www.w3.org/2001/XMLSchema#string

Numan Alabdan

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs.

Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to canadian dialysis centres.

Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

P304

e0188390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0188390

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yazed AlRuthia

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29182650

http://www.w3.org/2001/XMLSchema#string

P932

5705120

http://www.w3.org/2001/XMLSchema#string